20170313 FPI Kelly study FR
Catégorie : 2017
Vectorized gene therapy of liver tumors: proof-of-concept of TG4023 (MVA-FCU1) in combination with flucytosine
Faleh Husseini, et al.Annals of Oncology, February 2017, DOI: https://doi.org/10.1093/annonc/mdw440 – Download the articlePublication TG4023 is a non-replicative MVA integrating the FCU1 gene that has been inserted in the oncolytic virus TG6002.
Transgene et le Centre Léon Bérard annoncent le traitement du premier patient d’un essai clinique d’immunothérapie de Phase 1 évaluant la co-administration intratumorale de Pexa-Vec associé à l’Ipilimumab (Yervoy®) dans des cancers solides
20170213 ISI-JX FPI FR final
Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen
Gilda G. Hillman, et al. Journal for ImmunoTherapy of Cancer, January 2017 – Download the article Publication
Transgene présente son calendrier de communication financière pour 2017
20170105-Financial-calendar-FR
Transgene annonce la réussite de l’augmentation de capital avec maintien des DPS – Produit brut d’environ 46,4 millions d’euros
20161110 -TRANSGENE – CP Resultats
Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death-1 (PD-1) allow their intratumoral delivery and an improved tumor growth inhibition
Patricia Kleinpeter, et al.OncoImmunology, October 2016 – Download the articlePublication
Engineering Oncolytic Vaccinia Virus with Improved Cancer Killing Abilities
Johann Foloppe, et al.10th International Meeting on Replicating Oncolytic Virus Therapeutics, Vancouver, Canada – 1-4 October 2016Download the poster herePoster Presentation Collaboration between Transgene – HTS facility IGBMC, Illkirch – France IREBS, Illkirch, France – ICube, Strasbourg, France